Background: Studies suggest that colorectal cancer incidence increased disproportionately among the Aboriginal population of Ontario relative to the general population. Using an ecological approach, this study examined colorectal cancer incidence for the 1998-to-2009 period among Aboriginal people living in Ontario.
Data And Methods: Based on their postal code when they were diagnosed, cases of colorectal cancer identified from the Ontario Cancer Registry were assigned to census geographic areas with high (33% or more) or low percentages of Aboriginal identity residents, using the Postal Code Conversion File Plus (PCCF+). To account for potential misclassification by the PCCF+, Indian reserves for which assignment through postal codes is likely to be accurate were identified. Age-standardized incidence rates and rate ratios were calculated to compare colorectal cancer incidence in high-Aboriginal identity areas or on Indian reserves with incidence in low-Aboriginal identity areas.
Results: Colorectal cancer incidence was significantly higher for residents of high- versus low-Aboriginal identity areas in Ontario (rate ratio for men = 1.44, 95% CI = 1.26-1.63; rate ratio for women = 1.42, 95% CI = 1.23-1.63), a disparity that persisted by age group. When the Aboriginal sample was limited to residents of Indian reserves, the difference was statistically significant only for men and for people aged 50 to 74.
Interpretation: The incidence of colorectal cancer differs across areas of Ontario with high and low percentages of Aboriginal identity residents.
Download full-text PDF |
Source |
---|
Asia Pac J Clin Oncol
January 2025
Wellington Blood and Cancer Centre, Health New Zealand/Te Whatu Ora - Capital, Coast and Hutt Valley, Wellington, New Zealand.
Aim: Manatū Hauora, the Ministry of Health of New Zealand (NZ), published minimum standards for molecular testing of colorectal cancers (CRCs) in June 2018. These included mismatch repair (MMR) testing at diagnosis and BRAFV600E mutation analysis on newly diagnosed stage IV CRCs. This study aimed to determine the proportion of patients with CRC in the South Island of NZ with metastatic deficient mismatch repair (dMMR) CRC, the proportion of metastatic CRCs and dMMR CRCs that have a BRAFV600E mutation, and audit testing for BRAF mutations and appropriate referral to genetics services.
View Article and Find Full Text PDFAnn Surg
January 2025
Center for Surgical Science, Zealand University Hospital, Køge, Denmark.
Objective: This study investigated the association between loss of MSH2/MSH6 versus loss of MLH1/PMS2 expression and overall survival and disease-free survival in patients with localized colorectal cancer.
Background: The risk of developing colorectal cancer varies depending on the expression of mismatch repair proteins. However, it is unknown if the prognosis differs accordingly.
Food Funct
January 2025
Nutrition Innovation Centre for Food and Health (NICHE), Ulster University, Coleraine, UK.
Impairment of gut barrier integrity is associated with the pathogenesis of gastrointestinal diseases, including inflammatory bowel disease, colorectal cancer, and coeliac disease. While many aspects of diet have been linked to improved barrier function, (poly)phenols, a broad group of bioactive phytochemicals, are of potential interest. The (poly)phenolic sub-class, flavan-3-ols, have been investigated in some detail owing to their abundance in commonly consumed foods, including grapes, tea, apples, cocoa, berries, and nuts.
View Article and Find Full Text PDFMiddle East J Dig Dis
October 2024
Department of Colorectal Surgery, Colorectal Research Center, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran.
Background: Low anterior resection (LAR) is the gold standard for curative cancer treatment in the middle and upper rectum. In radically operated patients, the local recurrence rates with total mesorectal excision (TME) after 5 and 10 years was<10%, with 80% in 5 years survival. Anastomotic leakage (AL) affects 4%-20% of patients who underwent LAR.
View Article and Find Full Text PDFActa Pharm Sin B
December 2024
Institute of Biotechnology, Key Laboratory of Chemical Biology and Molecular Engineering of National Ministry of Education, Shanxi University, Taiyuan 030006, China.
Chemoresistance to 5-fluorouracil (5-FU) is a significant challenge in treating colorectal cancer (CRC). Novel combined regimens to thwart chemoresistance are therefore urgently needed. Herein, we demonstrated that the combination of Avenanthramide A (AVN A) and 5-FU has significant therapeutic advantages against CRC.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!